CAH patient’s survey from CAH International

Jun 30, 2023

Last year, CAH International held a first joint kick-off, on the basis of which working groups for research, surgery and standard of care were also formed.

The Standard of Care Working Group are mainly concerned with the issue of care at the moment. In order to learn more about the care in the different countries and to define their focus within the working group, they have developed a survey for CAH patients.

The main goal of the survey is to identify the lifestyle of patients and caregivers living with CAH worldwide. The results of the survey will be elaborated and further discussed in a dedicated workshop to plan further actions to address unmet needs and to share good practices.”

The survey can be found here. Please complete the survey by 15th July 2023.

The surveys are treated anonymously. For any questions, please contact manuela.broesamle@outlook.de

 

 

REMINDER: The Living with CAH Support Group and CAH International are not the same organisation. Please take this into consideration when completing their survey. We (the Living with CAH Support Group) are not responsible for any data that you share with CAH International. See Section 10 of our Privacy Policy here.

 

Recent Blog Posts

What you should know about COVID-19 – updated 10th August 2021

What you should know about COVID-19 – updated 10th August 2021

Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...

Survey: Paediatric Adrenal Insufficiency Education

Survey: Paediatric Adrenal Insufficiency Education

This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...

Treatment Research Update – Crinetics Atumelnant (CRN04894)

Treatment Research Update – Crinetics Atumelnant (CRN04894)

Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...

The CAH Support Group is affiliated with Society for Endocrinology, an organisation that supports clinicians, scientists and nurses who work with hormones throughout their careers. They engage policy-makers, journalists, patients and the public with hormone science to encourage informed health decisions, and to demonstrate the value of endocrinology to the wider world and also maintains a public information website, You and Your Hormones.

All content on this website (livingwithcah.com) is copyright the CAH Support Group unless otherwise stated.

The CAH Support Group cannot be held responsible for the content provided by any external links unless stated.

Cookie Policy | Privacy Policy | Disclaimer | Forum & Social Media Rules | Contact Us